Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis
The increase in the number of patients with type 2 diabetes mellitus (T2D) and mortality among them forces us to look for ways to optimize T2D treatment. At the same time, more than half of patients with an established diagnosis do not reach the glycemic targets and require intensification of therap...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2025-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13244 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729839132573696 |
|---|---|
| author | M. V. Shestakova G. R. Galstyan B. B. Kvasnikov E. E. Erina |
| author_facet | M. V. Shestakova G. R. Galstyan B. B. Kvasnikov E. E. Erina |
| author_sort | M. V. Shestakova |
| collection | DOAJ |
| description | The increase in the number of patients with type 2 diabetes mellitus (T2D) and mortality among them forces us to look for ways to optimize T2D treatment. At the same time, more than half of patients with an established diagnosis do not reach the glycemic targets and require intensification of therapy. Due to the progressive deterioration of the glycemic status, almost one in five T2D patients requires insulin therapy (IT), and over time, IT intensification with titration of the dose of insulin. This approach is limited by a few adverse effects such as: an increased risk of severe hypoglycemia, weight gain, decreased sodium excretion, which means fluid retention in the body, and the patient’s unwillingness to carry out complex therapy regimens. The addition of sodium-glucose cotransporter 2 (SGLT2i) inhibitor with an insulin–independent mechanism of action to the treatment is aimed to solve the problem of optimizing glycemic control in this category of T2D patients. The purpose of this network meta-analysis (NMA) was to indirectly compare the efficacy and safety of SGLT2 inhibitors added on top of insulin in T2D patients. The analysis included randomized clinical trials in which dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and ertugliflozin were prescribed as SGLT2i. The primary endpoint was a change in glycated hemoglobin (HbA1c), and the secondary endpoints were changes in a mean of fasting plasma glucose, body weight and blood pressure, as well as the mean change in daily dose of insulin. The analysis of safety data included a comparative assessment of the incidence of hypoglycemia, reproductive tract and urogenital infections, and hypovolemia. The results of the conducted NMA demonstrate the comparable effectiveness of various SGLT2i regarding managing of glycemic status in T2D patients receiving insulin, along with commensurate safety and tolerability of therapy. |
| format | Article |
| id | doaj-art-d4beb9e035cc4a71adb516edf859e46d |
| institution | DOAJ |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-d4beb9e035cc4a71adb516edf859e46d2025-08-20T03:09:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782025-01-0127654355410.14341/DM1324411138Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysisM. V. Shestakova0G. R. Galstyan1B. B. Kvasnikov2E. E. Erina3Endocrinology Research CentreEndocrinology Research CentreServier, Medical AffairsServier, Medical AffairsThe increase in the number of patients with type 2 diabetes mellitus (T2D) and mortality among them forces us to look for ways to optimize T2D treatment. At the same time, more than half of patients with an established diagnosis do not reach the glycemic targets and require intensification of therapy. Due to the progressive deterioration of the glycemic status, almost one in five T2D patients requires insulin therapy (IT), and over time, IT intensification with titration of the dose of insulin. This approach is limited by a few adverse effects such as: an increased risk of severe hypoglycemia, weight gain, decreased sodium excretion, which means fluid retention in the body, and the patient’s unwillingness to carry out complex therapy regimens. The addition of sodium-glucose cotransporter 2 (SGLT2i) inhibitor with an insulin–independent mechanism of action to the treatment is aimed to solve the problem of optimizing glycemic control in this category of T2D patients. The purpose of this network meta-analysis (NMA) was to indirectly compare the efficacy and safety of SGLT2 inhibitors added on top of insulin in T2D patients. The analysis included randomized clinical trials in which dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and ertugliflozin were prescribed as SGLT2i. The primary endpoint was a change in glycated hemoglobin (HbA1c), and the secondary endpoints were changes in a mean of fasting plasma glucose, body weight and blood pressure, as well as the mean change in daily dose of insulin. The analysis of safety data included a comparative assessment of the incidence of hypoglycemia, reproductive tract and urogenital infections, and hypovolemia. The results of the conducted NMA demonstrate the comparable effectiveness of various SGLT2i regarding managing of glycemic status in T2D patients receiving insulin, along with commensurate safety and tolerability of therapy.https://www.dia-endojournals.ru/jour/article/view/13244type 2 diabetes mellitussodium-glucose cotransporter-2efficacysafetyinsulin therapynetwork metaanalysis |
| spellingShingle | M. V. Shestakova G. R. Galstyan B. B. Kvasnikov E. E. Erina Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis Сахарный диабет type 2 diabetes mellitus sodium-glucose cotransporter-2 efficacy safety insulin therapy network metaanalysis |
| title | Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis |
| title_full | Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis |
| title_fullStr | Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis |
| title_full_unstemmed | Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis |
| title_short | Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis |
| title_sort | efficacy and safety of sodium glucose cotransporter 2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin a network meta analysis |
| topic | type 2 diabetes mellitus sodium-glucose cotransporter-2 efficacy safety insulin therapy network metaanalysis |
| url | https://www.dia-endojournals.ru/jour/article/view/13244 |
| work_keys_str_mv | AT mvshestakova efficacyandsafetyofsodiumglucosecotransporter2inhibitorsintype2diabetesmellituswithinadequateglycemiccontroloninsulinanetworkmetaanalysis AT grgalstyan efficacyandsafetyofsodiumglucosecotransporter2inhibitorsintype2diabetesmellituswithinadequateglycemiccontroloninsulinanetworkmetaanalysis AT bbkvasnikov efficacyandsafetyofsodiumglucosecotransporter2inhibitorsintype2diabetesmellituswithinadequateglycemiccontroloninsulinanetworkmetaanalysis AT eeerina efficacyandsafetyofsodiumglucosecotransporter2inhibitorsintype2diabetesmellituswithinadequateglycemiccontroloninsulinanetworkmetaanalysis |